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The development of antibiotic resistance during treatment is a threat to patients and their 
environment. Insight in the mechanisms of resistance development is important for appropriate 
therapy and infection control. Here, we describe how through the application of mass spectrometry-
based proteomics, a novel beta-lactamase Axc was identified as an indicator of acquired carbapenem 
resistance in a clinical isolate of Achromobacter xylosoxidans. Comparative proteomic analysis of 
consecutively collected susceptible and resistant isolates from the same patient revealed that high Axc 
protein levels were only observed in the resistant isolate. Heterologous expression of Axc in Escherichia 
coli significantly increased the resistance towards carbapenems. Importantly, direct Axc mediated 
hydrolysis of imipenem was demonstrated using pH shift assays and 1H-NMR, confirming Axc as a 
legitimate carbapenemase. Whole genome sequencing revealed that the susceptible and resistant 
isolates were remarkably similar. Together these findings provide a molecular context for the fast 
development of meropenem resistance in A. xylosoxidans during treatment and demonstrate the use of 
mass spectrometric techniques in identifying novel resistance determinants.
Development and spread of antibiotic resistance by pathogenic microorganisms is an increasing healthcare prob-
lem. Moreover, certain resistance determinants spread readily1,2, while the introduction of novel antibiotics is 
lagging behind. Several clinically important classes of antimicrobials such as the beta-lactams, target the bacterial 
cell wall3. Resistance to beta-lactams can be mediated by beta-lactamases that are capable of hydrolysing the 
beta-lactam ring. Following the initial introduction of penicillin, second and third generation beta-lactams have 
been developed which, in turn, triggered the selection of beta-lactamases with broader specificities. Carbapenem 
treatment is often used as a last resort, since extended-spectrum beta-lactamases (cephalosporinases) are becom-
ing more prevalent in Gram-negative bacteria. The emergence and spread of carbapenemases such as class A KPC4, 
a number of metallo beta-lactamases5,6 (class B: IMP, VIM, NDM) and class D oxacillinases such as OXA-487, 
in combination with other resistance mechanisms8, can jeopardize carbapenem efficacy, leaving little or no treat-
ment options for patients.
Achromobacter xylosoxidans is a rod shaped aerobic non-fermentative Gram-negative bacterium. It is wide-
spread in the environment and generally considered as an opportunistic pathogen. Chronic infections with 
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A. xylosoxidans are problematic in cystic fibrosis patients9,10 but reported prevalence numbers vary greatly 
(3–30%)11,12. Moreover, bacteremia as a result of A. xylosoxidans can occur in immunocompromised patients13. A. 
xylosoxidans is notorious for its intrinsic high level of resistance, especially towards penicillins and cephalospor-
ins14–16. In general, carbapenem resistance in A. xylosoxidans is not widespread and as a result meropenem treat-
ment is routinely applied, even in the case of recurring infections17,18. Though carbapenem resistance is observed, 
specifically for meropenem19, there are few reports on the mechanism of carbapenemase resistance in A. xylosoxi-
dans. Notable exceptions are the plasmid-encoded carbapenemase IMP20,21 and the chromosomally encoded class 
D beta-lactamase OXA-11416, that show low level carbapenemase activity. A comparative genomic exploration of 
two A. xylosoxidans isolates revealed many genes that could be involved in drug resistance, such as efflux pumps 
and β-lactamases. However, most of these genes were conserved between carbapenem susceptible and resistant 
strains, highlighting the difficulty in translating genomic data to the observed resistant phenotypes22.
In this study, two clinical isolates of A. xylosoxidans from an immunocompromised patient with pneumonia 
were investigated. The initially cultured isolate from the respiratory tract was susceptible to meropenem and 
treatment was started accordingly. However, a subsequent meropenem resistant isolate was obtained from a blood 
culture after treatment failure. Since PCR analysis was negative for known carbapenemases, we performed a 
proteomic analysis which revealed the novel beta-lactamase Axc as highly abundant in the meropenem-resistant, 
but not in the susceptible isolate. Axc expression led to an increase of minimal inhibitory concentrations for car-
bapenems when introduced in a susceptible Escherichia coli strain and direct carbapenemase activity of Axc was 
demonstrated using in vitro imipenem conversion assays. Interestingly, the resistant and the susceptible clinical 
isolates are genetically almost identical, emphasizing the importance of mass spectrometry as a technique to 
investigate carbapenem resistance in A. xylosoxidans.
Results
Development of meropenem resistance in Achromobacter xylosoxidans during treatment. An 
antibiogram of a clinical isolate of Achromobacter xylosoxidans from a patient treated for pneumonia (see 
Methods for details about patient history and treatment) revealed a multi-resistant character, but it was suscep-
tible to meropenem (Supplemental Table 1). Hence, meropenem treatment was initiated. During treatment, the 
patient developed a pneumothorax and died from septic shock 6 days later. An antibiogram of a blood culture 
from a sample taken one day before the patient’s death revealed a meropenem-resistant A. xylosoxidans phe-
notype (Supplemental Table 1). Subsequently, pure cultures from the first and second clinical isolate were pre-
pared (AchroS and AchroR, respectively (Table 1)). In line with the antibiogram analysis described above, Etests 
showed that both isolates were resistant to imipenem (MIC > 32 mg/L for both) but differed in their susceptibility 
towards meropenem (MIC of 0.0094 mg/L (first isolate, AchroS) and 2 mg/L (second isolate, AchroR), respec-
tively). An in-house multiplex PCR assay (based on a published PCR)23 failed to detect common carbapenemases 
(KPC, IMP, VIM, NDM and OXA-48, data not shown), suggesting that the change in resistance is not mediated 
by these enzymes. This finding prompted us to perform a comparative proteomic analysis of the two isolates to 
attempt to identify the meropenem resistance mechanism.
Comparative proteomic analysis shows differential levels of the beta-lactamase Axc. Protein 
extracts of the meropenem-susceptible and resistant A. xylosoxidans isolates (AchroS and AchroR) were first 
analysed by SDS-PAGE. Since no major visual differences were observed (Supplemental Fig. S1A), all bands were 
excised and processed for a bottom-up LC-MS/MS proteomic analysis. In total, 2276 unique proteins were iden-
tified, of which 1519 proteins were common to both isolates, while 223 and 534 were only found in the susceptible 
and resistant isolates, respectively. For a semi-quantitative analysis, the spectra assigned to peptides belonging to 
a certain protein were counted and compared between the two different isolates (Supplemental Figs S1B and S2, 
Table S2). Of the uniquely observed proteins, most were proteins with low spectral counts (often single peptide 
identifications), likely resulting from sampling bias of low abundant proteins. One protein was observed with 
102 spectra in the resistant isolate (AchroR) but none in the susceptible isolate (AchroS). This protein, hereafter 
called Axc (for Achromobacter xylosoxidans carbapenemase, GenBank ID: MF767301), is a putative PenP class A 
beta-lactamase (COG2367/pfam13354).
To confirm that Axc was highly abundant in the resistant isolate in comparison to the susceptible isolate, a sec-
ond proteomic analysis was performed on whole cell protein extracts that were digested in-solution and analysed 
without any prior fractionation. Spectral count analysis resulted in a cumulative quantification of 1342 different 
proteins, of which 981 were found in both isolates, but 196 and 165 were uniquely quantified in the susceptible 
and resistant isolates, respectively. The spectral count plot reflects the high similarity of the two clinical isolates, 
with the vast majority of the proteins distributed along the diagonal (Fig. 1A, Table S2, Supplemental Fig. S2). In 
Name Short description Full description
JC188 AchroS Meropenem susceptible A. xylosoxidans clinical isolate
JC186 AchroR Meropenem resistant A. xylosoxidans clinical isolate
JC107 E. coli_Axc Escherichia coli C43/pET21B-Axc
JC108 E. coli_control Escherichia coli C43/pET21B-PPEP-1
JC113 KPC Carbapenemase positive Klebsiella pneumoniae
Table 1. Strains used in this study. Axc: Achromobacter xylosoxidans carbapenemase. PPEP-1: Pro-Pro 
endopeptidase 131.
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accordance with the data described above, Axc was the most prominent outlier in the resistant clinical isolate. A 
number of Axc tryptic peptides (Fig. 1B) was clearly visible in the LC-MS/MS analysis of the resistant but not the 
susceptible isolates (Fig. 1C). Of note, cells used for these analyses were grown in the absence of meropenem, so 
the high level of Axc in the resistant isolate was independent of antibiotic pressure.
The axc gene is present in meropenem resistant and susceptible A. xylosoxidans isolates. To 
investigate whether A. xylosoxidans acquired the axc gene in the course of the treatment, we performed a PCR 
for the axc open reading frame on both the resistant and susceptible isolates AchroS and AchroR. This analysis 
demonstrated that axc was present in both clinical isolates (Supplemental Fig. S3A). Moreover, Sanger sequence 
Figure 1. Comparative proteomic analysis of meropenem resistant and susceptible Achromobacter xylosoxidans 
clinical isolates. (A) Tryptic digests of protein extracts of the meropenem resistant (AchroR, Table 1) and 
susceptible (AchroS, Table 1) isolate were analysed by LC-MS/MS. Spectra were assigned to peptides based on 
database searching. Identified spectra were then assigned to the corresponding proteins and the total number 
of spectra per protein were counted. Each circle represents one protein with the number of spectra observed 
in the resistant and the susceptible isolate. Hence, proteins on the diagonal were observed in similar counts in 
both isolates. Axc (arrow), a classA PenP-family beta-lactamase, is the most prominent outlier. See also Table S2 
and Supplemental Fig. S2. (B) The full amino acid sequence of Axc, with the peptides identified by LC-MS/MS 
analysis underlined. Conserved residues from serine beta-lactamases, Ser-X-X-Lys, Ser-Asp-Asn and the active 
site Glu, are in bold37. (C) Extracted ion chromatograms of m/z values corresponding to tryptic peptides of Axc 
in the meropenem resistant isolate (AchroR, upper panel) and susceptible isolate (AchroS, lower panel). The 
corresponding tryptic peptides are indicated above the corresponding peaks.
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analysis demonstrated that the sequence of axc was identical in both isolates (data not shown), indicating that the 
observed meropenem resistance was not likely caused by an alteration of protein function.
A database search revealed that the axc gene is not present in all A. xylosoxidans strains (Fig. 2A). Like in 
our clinical isolates, axc is present in the NH44784-1996 strain (ENA assembly GCA_000967095.1)24 but 
not in the strains NBRC 15126/ATCC 27061 (ENA assembly GCA_000508285.1) and C54 (ENA assembly 
GCA_000758265.1) for instance. In those strains that contain axc, the gene is located next to a putative LysR-type 
transcriptional regulator (Pfam 03466), hereafter axcR (for axc-associated regulator). Additional PCR and Sanger 
sequencing experiments verified that the intergenic regions between axc and axcR in AchroS and AchroR were 
identical. However, they differed at two positions with the intergenic region between axc and axcR in strain 
NH44784_1996 (Supplemental Fig. S3B).
The results showed a high degree of similarity between the meropenem resistant and susceptible strain, rais-
ing the possibility that these two strains represented a clonal complex. To further explore the relatedness of both 
Figure 2. Genomic context of axc in Achromobacter xylosoxidans strains and comparison of Axc with other 
class A beta-lactamases (A) Axc (a putative PenP class A beta-lactamase, 1.17 e-54) and the gene encoding its 
putative transcriptional repressor (axcR), were found in both clinical isolates (AchroS and AchroR, Table 1). 
Three other fully sequenced genomes of Achromobacter xylosoxidans were examined for the presence of 
axc; NH44784_1996 (ENA assembly GCA_000967095.1), C54 (ENA assembly GCA_000758265.1) and 
NBRC_15126/ATCC27061 (ENA assembly GCA_000508285.1). Only within the strain NH44784_1996 (used 
as a reference to search our proteomics data), axc and the putative regulator are also present. (B) Unrooted 
cladogram obtained for 176 class A beta-lactamases including Axc. The class A β-lactamase protein sequences 
of Gram negative bacteria were obtained by querying the refseq_protein database using Blastp (<1e-10, http://
blast.ncbi.nlm.nih.gov/blast/Blast.cgi) and a consensus β-lactamase-alignment37. Duplicate sequences and 
sequences causing a strong overrepresentation of branches produced in the tree were removed. Names of known 
carbapenames (orange) and names of identifier of branches37 are indicated. Axc is indicated with a red dot. The 
closest homologue to Axc, a β-lactamase from R. saidenbachensis (WP_029709665), is also indicated.
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isolates, whole genome sequencing (WGS) analysis was performed. This showed that both patient isolates were 
highly similar, with only one single-nucleotide polymorphism (SNP) within the gene encoding AxyZ25. This SNP 
was confirmed by PCR and subsequent Sanger sequencing, ruling out the possibility that this was an artefact 
of the assembly procedure. Moreover, axc and its putative regulator axcR were found to be located in the same 
genomic region as in NH44784_1996 strain (Fig. 2A). Overall, the genome sequences suggest that both isolates 
are clonal, and that the meropenem resistance evolved within the same strain during the course of treatment.
To demonstrate how Axc is related to other class A beta-lactamases, we compared the Axc amino acid sequence 
with the sequence of another 176 representatives of this family using an alignment consensus based on a report 
by Walther-Rasmussen and Hoiby26. The resulting unrooted cladogram shows that Axc is most closely related to 
a class A beta-lactamase of Rhodoferax saidenbachensis (WP_029709665, Fig. 2B). Only a limited number of class 
A beta-lactamases have activity towards carbapenems, but none of these cluster with the Axc sequence (Fig. 2B).
Functional characterisation of Axc. To establish whether Axc indeed has activity towards carbapenems, 
Axc was expressed in a heterologous host and hydrolysis of carbapenems was measured indirectly and directly.
The E. coli C43 strain, suitable for the expression of toxic proteins27, is susceptible to carbapenems. We gener-
ated a derivative of C43 that allows for IPTG-dependent expression of a plasmid-based copy of axc (E. coli_Axc 
(JC107)). Susceptibility testing for imipenem and meropenem showed that the MICs for these carbapenems 
increased 8-fold, following induction of Axc expression (Table 2). Though these levels were lower than for the 
positive control (KPC) for our assay, they were specific for Axc as the expression of an unrelated protein (PPEP-1)28  
did not lead to an increase in MIC values (Table 2). Thus, expression of Axc is correlated to resistance towards 
carbapenems.
To directly demonstrate carbapenemase activity, hydrolysis of imipenem was monitored in vitro through col-
orimetric assays (Fig. 3A) and 1H-NMR (Fig. 3B). Imipenem hydrolysis results in the formation of a carboxylic 
acid, and monitoring the accompanying pH drop colorimetrically is a well-established method for the detection 
of carbapenemase activity29,30. Indeed, hydrolysis of imipenem was readily observed using KPC cells (without 
IPTG). Consistent with our previous results, imipenem hydrolysis was observed for E. coli cells harbouring the 
Axc expression plasmid (E. coli_Axc) grown in the presence, but not in the absence, of IPTG. As before, these 
results were specific for Axc, as induction of PPEP-1 expression (E.coli_control) did not result in imipenem 
hydrolysis (Fig. 3A). In a parallel assay, 1H-NMR was used to directly observe the opening (hydrolysis) of the 
lactam ring in imipenem (Fig. 3B). The chemical shifts of the peaks change as a result of this hydrolysis, with 
the protons closest to the ring opening undergoing the largest change. The H-6 proton of imipenem generates 
an adequately resolved multiplet at 3.42 ppm that decreases in intensity upon hydrolysis. Concomitantly, the 
doublet generated by the protons of the methyl group (H-9) move upfield, resulting in a decrease of the doublet 
at 1.3 ppm. After 10 minutes incubation of bacterial cells with imipenem, hydrolysis of imipenem was observed 
with E. coli_Axc grown in the presence, but not in the absence, of IPTG. Hydrolysis was also apparent for KPC, 
but not for E. coli cells expressing PPEP-1 (E.coli_control)), even after long incubation times (10 h). Under these 
conditions, imipenem hydrolysis was also observed for samples with E. coli cells harbouring the Axc expression 
plasmid grown in absence of IPTG, due to leaky expression from the inducible promoter.
Taken together, our data establish that Axc has carbapenemase activity.
Discussion
In this paper we identified a new resistance mechanism that explains the difference in meropenem susceptibility of 
two clinical isolates of A. xylosoxidans that were collected during treatment. Using a combination of comparative 
proteomic analyses and functional assays, we have shown that the class A beta-lactamase Axc is highly abundant in 
the meropenem resistant isolate in comparison to the susceptible isolate and that Axc has carbapenemase activity.
Detection of carbapenemases from sequence data is challenging. First, carbapenemases belong to different 
subgroups of beta-lactamases which have probably evolved by convergent evolution. Although sequence iden-
tities are moderate, most of the class A carbapenemases have a disulphide bridge between Cys-69 and Cys-238, 
but this is dispensable for activity against carbapenems31 and our data show that Axc does not contain these 
residues. Next, some studies also revealed a mechanism where beta-lactam trapping, without actual degradation, 
can be involved in resistance towards carbapenems when levels are sufficiently high. In such cases, concomitant 
loss of porins is often observed32,33. Thus, it is crucial to determine whether a beta-lactamase actually induces 
hydrolysis of carbapenems. Our NMR and pH-shift analyses data clearly demonstrate Axc-mediated opening of 




−IPTG +IPTG −IPTG +IPTG
E. coli_ Axca 0.5 4 1.563 12.5
E. coli_controlb 0.38 N.D. 0.391 0.391
KPCc >32 >32 >12.5 >12.5
Table 2. Effect of Axc expression in E. coli on the susceptibility towards imipenem and meropenem. Minimal 
inhibitory concentrations of imipenem and meropenem for E.coli C43 expressing Axc (E. coli_ Axc), or PPEP-1 
(E. coli_control) and Klesbsiella pneumoniae expressing KPC carbapenemase (KPC). N.D: Not detectable. IPTG: 
isopropyl β-D-1-thiogalactopyranoside. aJC107: Escherichia coli C43/pET21B-Axc. bJC108:Escherichia coli C43/
pET21B/PPEP-1 (Pro-Pro endopeptidase 1). cJC113: Carbapenemase-positive Klebsiella pneumonia.
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instance, a recent study demonstrated plasmid derived carbapenem resistance in Klebsiella pneumoniae strains 
which could not be explained by the most commonly found carbapenemases (KPC-type). Even though none of 
the plasmid-encoded genes were obvious candidates for the observed resistance towards carbapenems, several 
TEM-homologs were detected34. Though the prediction of the activity of a certain beta-lactamase against carbap-
enems is not straightforward, studies such as the present one highlight that mass spectrometry approaches can be 
used to gain insight in the mechanism of action and role of specific proteins in the observed phenotypes.
We do not know whether the high level of Axc is the only mechanism conferring meropenem resistance to 
our isolate of A. xylosoxidans. When expressed from an inducible promoter, Axc confers moderate resistance 
to carbapenems to E. coli; MIC values compared to the KPC strain suggest that Axc has a lower efficiency than 
KPC, but may also indicate lower overall levels of expression. Differing efficiencies in carbapenemases are well 
documented, to the point where the activity of a specific class, such as OXA-48, is difficult to detect but of great 
clinical importance35. Full biochemical characterization of Axc, including kinetic experiments, is subject to fur-
ther study. Such experiments, in combination with crystallography analysis, will provide more insight in the 
activity of Axc against different beta-lactams and could resolve the structural characteristics of the binding pocket 
Figure 3. Axc has carbapenemase activity. (A) Axc was expressed in E. coli and cell extracts were tested for the 
ability to hydrolyse imipenem. Bars show the A431/A560 ratio, which is a measure for the shift in pH due to 
imipenem hydrolysis. (B) NMR-based identification of imipenem hydrolysis by Axc. The structure of imipenem 
is shown, with the proton numbering used in the spectrum. The line color indicates the incubation time (red, 
10 min at room temperature or black, 10 hrs at 6 °C). Imipenem hydrolysis is accompanied by the loss of the H-6 
multiplet at 3.4 ppm, and a shift in the H-9 doublet, resulting in a decrease of the doublet at 1.3 ppm. Strains 
used (see also Table 1): KPC (JC113): Carbapenem resistant Klebsiella pneumoniae. E. coli Axc (JC107): E. coli 
strain C43(DE3), containing plasmid pET21-Axc; E. coli_control (JC108): E. coli strain C43, containing plasmid 
pET21-PPEP-1 (Pro-Pro endopeptidase 1). IPTG: isopropyl β-D-1-thiogalactopyranoside.
www.nature.com/scientificreports/
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which facilitates its activity towards carbapenems. We note, however, that two other changes in the antibiogram 
between the meropenem susceptible and resistant isolates involve beta-lactam antibiotics. Augmentin (amox-
icillin/clavulanate) resistance changed from intermediate (8 mg/L) to resistant (>32 mg/L), and piperacilline/
tazobactam from susceptible (< = 4 mg/L) to intermediate resistance (8 mg/L). This suggests that Axc may have 
a broad substrate specificity and is insensitive to inhibition by clavulanate and tazobactam. Strikingly, both the 
meropenem-susceptible and meropenem-resistant isolates were resistant to imipenem (MIC values higher than 
the maximum concentration tested (32 mg/L)). This indicates that, notwithstanding the activity of Axc towards 
imipenem as presented here, imipenem resistance in the clinical isolates is not dependent on Axc. Differences 
in the sensitivities towards different carbapenems results from the chemical differences between the individual 
drugs36 and are often linked to the differential permeability of the outer cell membrane37,38.
The regulatory mechanism leading to higher levels of Axc expression are unclear. Sequence analyses 
showed that the meropenem susceptible and resistant A. xylosoxidans clinical isolates are highly similar, with 
no differences in the axc promotor and coding sequence, nor in its putative regulator AxcR and the axc-axcR 
intergenic region. The only SNP we identified is located in the gene encoding AxyZ, the TetR-type repres-
sor of the axyXY-oprZ operon25. This leads to an amino acid substitution (V29G) in a region of AxyZ that is 
involved in DNA binding in other members of TetR family39. AxyX, AxyY and OprZ form an efflux pump of 
the resistance-nodulation division (RND) family and are predominantly found in aminoglycoside resistant 
Achromobacter species40–42. A recent paper showed higher expression levels of axyY in A. xylosoxidans strains 
containing AxyZ_Gly29, suggesting that this mutation leads to reduced repression of AxyZ43. Closer inspection 
of our proteomics data indicates that also AxyX and AxyY are more abundant in the resistant isolate (spectral 
counts of 62 vs 21 for AxyX and 10 vs 2 for AxyY in the results presented in Fig. 1 (see Table S2)). However, the 
difference is not as pronounced as found for Axc and more accurate quantitative proteomics experiments have to 
be performed to validate these data.
Mutations in TetR-like repressors have been linked to differences in carbapenem resistance44. For example, a 162 bp 
deletion in axyZ has been identified in certain carbapenem resistant strains45. However, even though AxyZ_Gly29 
leads to higher expression of axyY, resulting in higher MIC values for aminoglycosides, fluoroquinolones and 
tetracyclines, no correlation between axyY expression and meropenem resistance was observed43. In line with this 
observation, a deletion of axyY in several A. xylosoxidans strains is reported to result in only a modest increase in 
the susceptibility towards carbapenems25. Taken together, it is likely that AxyXY-OprZ per se contributes little if 
any to the meropenem resistance phenotype of our clinical isolate. Instead, our data show a critical role for Axc 
and suggest that axc expression is regulated by AxyZ. If this is indeed the case, we postulate that the increase in the 
meropenem MIC for the ACH-CF-911V29G strain43 is accompanied by increased Axc levels.
From the clinical perspective, the development of resistance to meropenem within days following meropenem 
treatment is remarkable. Previous longitudinal analyses of different A. xylosoxidans isolates from one patient have 
revealed large phenotypic and genetic differences, for example in the resistance towards different classes of antibi-
otics but they were generally performed over longer time periods24,44,45. Such changes are believed to be the result 
of adaptive evolution of the initial strain which infected the patient, but there is also evidence that genetically dif-
ferent strains of A. xylosoxidans can co-exist within the same chronically infected individual46. Though we cannot 
exclude a co-infection, it is likely that the mutation in axyZ in our case occurred during treatment.
Finally, from a diagnostic point of view, the presence of Axc in both the sensitive and resistant A. xylosoxidans 
isolates complicates straightforward detection by molecular methods in the future and warrants detection based 
on protein abundance levels. Even though more elaborate mass spectrometry-based platforms clearly have poten-
tial for the detection of resistance and virulence proteins47,48, as also exemplified in our study, it will take more 
time and effort before they could find their way into the medical microbiology laboratory to complement the now 
well-established application of MALDI-ToF-MS for bacterial species identification.
Methods
Patient history. All procedures performed in studies involving human participants were in accordance with 
the ethical standards of LUMC Medical Ethical Committee and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards.
A 65-year old patient, diagnosed with chronic lymphocytic leukemia in 1989, underwent a non-myeloablative 
stem cell transplantation in July 2014. The patient was discharged on July 25th but readmitted on August 1st 
with a mucositis-associated neutropenic fever and blood cultures positive for Gemella haemolysans. The patient 
was treated with cefuroxim intravenously but developed pneumonia one week later. Analysis of a sputum sam-
ple showed a microscopically and culture confirmed fungal infection and abundant growth of a Gram-negative 
bacterium. This bacterium was identified as A. xylosoxidans by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry. The patient was treated with liposomal amphotericin B for the fungal infection, 
but this did not result in improvement of the patient’s status. Due to clinical deterioration the patient received 
ceftazidim (3 dd 1 gram intravenously) between September 3rd and 9th to treat the ceftazidim sensitive A. xylosox-
idans isolate. On September 10th, the antibiogram (Supplemental Table 1), revealed a multi-resistant character for 
the A. xylosoxidans isolate, but it was susceptible to meropenem. Hence, meropenem treatment was initiated (4 
dd 1 gram intravenously) on September 10th. During treatment the patient developed a pneumothorax and died 
from septic shock 6 days later. Because of this, informed consent of the patient was not possible to obtain. We 
therefore anonymized all patient data and presented the data in such a form that it is not traceable to the patient.
Materials. MilliQ water was obtained from a Q-Gard 2 system (Merck Millipore, Amsterdam the 
Netherlands). Acetonitrile of LC-MS grade was obtained from Biosolve (Valkenswaard, the Netherlands). Porcine 
trypsin was purchased from Promega (Madison, WI). If not indicated otherwise, chemicals were from Sigma 
Aldrich (St Louis, MN, USA).
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Susceptibility profiling of clinical isolates. The minimum inhibitory concentrations (MICs) for dif-
ferent antibiotic compounds on the clinical isolates (Clinical IDs: M 14073954-7 (first isolate), M 14076260-2 
(second isolate)) were initially determined using a Vitek-2 system (bioMérieux, Marcy-l’Étoile, France). Several 
colonies of plate grown cultures were inoculated and suspended in 0.45% sterile physiological saline solution. 
Suspensions for testing had densities between of approx. 0.5 McFarland standards. The testing procedure was 
performed according to the manufacturer’s instructions.
Pure cultures of the susceptible and resistant isolates (AchroS and AchroR, respectively (Table 1)) were sub-
jected to further susceptibility testing and used for the proteomic and genomic analyses. Etests (bioMérieux) were 
performed according to the recommendations from EUCAST (http://www.eucast.org/clinical_breakpoints/). 
EUCAST does not provide recommendations for the interpretation of MIC values or clinical breakpoints for 
Achromobacter xylosoxidans. Therefore, scoring was performed using locally developed protocols that are based 
on clinical breakpoints for other non-fermentative Gram-negative rods.
Mass spectrometry-based proteomics. Cells were grown in BHI (Oxoid, Basingstoke, UK). Cells were 
collected by centrifugation (4000 g, 5 min) from 1 mL cell culture and washed with phosphate- buffered saline 
(PBS, pH 7.4). Pellets were stored at −80 °C until further use.
Two different proteomics experiments were performed. For the first, cell extracts from A. xylosoxidans strains 
(AchroS and AchroR, Table 1) were prepared in LDS (Lithium dodecyl sulphate) sample buffer (Novex, Thermo 
Scientific) and put at 95 °C for 5 minutes for cell lysis and protein extraction. Proteins were separated on Novex 
precast 4–12% Bis-Tris gels (Thermo Scientific, Waltham, MA, USA) with MOPS (3-(N-morpholino)pro-
panesulfonic acid) running buffer (Thermo Scientific). After overnight staining using a Colloidal Blue Staining 
Kit (Thermo Scientific), destained gel lanes were processed into 31 slices per lane. Gel pieces were sequentially 
washed with 25 mM ammonium bicarbonate and acetonitrile. Reduction and alkylation were performed with 
dithiothreitol (DTT, 10 mM, 30 minutes at 56 °C) and iodoacetamide (IAA, 55 mM, 20 min at room temperature) 
respectively. Following several washes with 25 mM ammonium bicarbonate and acetonitrile, bands were over-
night digested with trypsin (12.5 ng/μl in 25 mM NH4HCO3). Digest solutions were lyophilized and reconstituted 
in 0.5% trifluoroacetic acid (TFA). Nano-LC separation was carried out using a Ultimate 3000 RSLCnano System 
equipped with an Acclaim PepMap RSLC column (C18, 75 µm × 15 cm with 2 µm particles, Thermo Scientific) 
preceded by a 2 cm Acclaim PepMap100 guard column (Thermo Scientific). Peptide elution was performed by 
applying a mixture of solvents A and B with solvent A being 0.1% formic acid (FA) in water and solvent B 0.1% 
FA in 80% acetonitrile (ACN). Peptides were eluted from the column with a multi-step gradient from 5% to 55% 
solvent B in 55 minutes (0–5 min 5%B, then in 15 min to 20%B and finally in 25 min till 55%B), at a constant flow 
rate of 300 nl min−1. MS analysis was performed employing a maXis Impact UHR-TOF-MS (Bruker Daltonics, 
Bremen, Germany) in data dependent MS/MS mode in the m/z 150–2200 range. The source settings were as fol-
lows: voltage 1500 V, dry gas 3.0 l.min−1, temperature 150 °C. Ten ions were selected at a time, based on relative 
abundance and subjected to collision-induced-dissociation with helium as collision gas. A 1 minute dynamic 
exclusion window was applied for precursor selection. The precursor isolation window and collision energy were 
m/z dependent.
For the second proteomics approach, in-solution digests were prepared as described previously47. In short, 
following cell disruption proteins were solubilized in 50% trifluoroethanol (TFE). Subsequent reduction with 
DTT and alkylation with IAA were performed prior to overnight tryptic digestion. Samples were lyophilized and 
reconstituted in 0.5% TFA for injection. The nano-LC system and solvents were the same as in the above experi-
ment, but using an Acclaim PepMap RSLC column (C18, 75 µm × 50 cm with 2 µm particles, Thermo Scientific) 
with a 2 cm Acclaim PepMap100 guard column (Thermo Scientific). Peptides were eluted from the column with 
a multi-step gradient from 5% to 55% of solvent B in 180 minutes (0–5 min 5%B, then in 65 min till 13%B, then 
in 90 minutes till 35%B and finally in 20 min till 55%B), at a constant flow rate of 300 nl min−1. MS analysis was 
carried out as described above.
Mass spectrometry data export and spectral count analysis. Conversion of Bruker Impact files into 
mzXML format using CompassXport version 3.0.9, led to an initial total of 1,207,329 MS/MS and 444,565 MS/MS 
spectra, for the gel and total lysate based comparisons, respectively (in-solution total lysate digests were analysed 
twice and the data were merged). These spectra were searched using a concatenated forward and decoy strategy. 
The forward database was constructed from the 6386 unreviewed sequences from Uniprot for the organism A. 
xylosoxidans NH44784-1996 (November 2015) together with the cRAP contaminant sequences, as downloaded 
in January 2015. An in-house developed program, Decoy version V1.0.1-2-gfddc, that preserves homology, 
amino-acid frequency and peptide length distribution, was used with default flags to construct the decoy search 
space, which was concatenated to the forward sequences. The search against the resulting database was performed 
using Comet version 2014.02 rev.2, with precursor mass tolerance equal to 50 ppm and a fragment bin width 
of 0.05 Da, considering only fully tryptic digests with at most 2 missed cleavages. All cysteines were assumed 
carbamidomethylated, while methionine oxidation and N-terminal acetylation were regarded as variable modi-
fications. The confidence of these results was assessed by means of Xinteract from the Trans Proteomics Pipeline 
suite version 4.8.0, retaining peptides longer than 6 amino acids and running in semi-parametric mode. A second 
in-house developed program, Pepxmltool version 2.5.1, was used to construct a protein quantification table based 
on spectral counting of only non-degenerate peptides (peptides mapping to a single protein) with corresponding 
q-value of at most 1%. Plots of the resistant versus susceptible quantifications of all proteins revealed for both 
methods a predominantly linear relationship, suggesting the applicability of an in-house developed program, 
Qntdiff version 0.1.1, to assign p-values to deviations from linear behaviour and provide lists of the most signif-
icantly differential protein expression levels between the two isolates. The programs Pepxmltool and Qntdiff are 
available from the authors on request.
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Bacterial culture and genomic DNA preparation. AchroS and AchroR (Table 1) were cultured on tryp-
case soy agar plates (BioMérieux, Marcy l’Etoile, France), inoculated into liquid medium brain-heart-infusion 
(BHI) broth (Oxoid, Basingstoke, UK) and grown overnight (~16-hrs) at 37 °C. Cells were harvested, washed with 
phosphate-buffered saline (PBS, pH 7.4), and genomic DNA extraction was performed using a phenol-chloroform 
extraction as previously described49.
Whole genome sequencing and SNP calling. Paired-end multiplex libraries were created as previously 
described50. Sequencing was performed on an Illumina Hiseq 2000 platform (Illumina, San Diego, Ca, USA), 
with a read-length of 100 basepairs. High-throughput de novo assembly of sequenced genome was performed as 
previously described51,52. The assemblies are then automatically annotated using PROKKA53 with genus-specific 
databases from RefSeq54. To identify single nucleotide polymorphisms (SNPs), the Illumina sequence data of 
the meropenem-susceptible A. xylosoxidans isolate (AchroS) was mapped on the assembled genome of the 
meropenem-resistant isolate (AchroR) using SMALT software (http://smalt.sourceforge.net/), after which SNPs 
were determined as previously described50.
PCR and heterologous expression of Axc. To corroborate the proteomics results and confirm results 
from the whole genome sequence analysis, the axc ORF, the axc-axcR intergenic region and part of the axyZ 
ORF were Sanger sequenced at a commercial provider (Macrogen, Amsterdam, the Netherlands). PCR products 
(for primers see Table 3) were sequenced using the same primers as those used for generating the product from 
genomic DNA isolated from the A. xylosoxidans isolates. We have submitted the Axc sequence to Genbank, ID 
MF767301.
To construct an E. coli strain expressing Axc with a C-terminal 6xHis-tag from an IPTG (isopropyl 
β-D-1-thiogalactopyranoside) inducible promoter, the axc open reading frame was amplified using primers 
Axfor2 and Axrev3 (Table 3), using Accuzyme polymerase (GC Biotech, Alphen aan den Rijn, The Netherlands) 
and genomic DNA from A. xylosoxidans (AchroR) as a template. The amplified PCR product was digested using 
NdeI (Bioké, Leiden, The Netherlands) and XhoI (Roche, Almere, The Netherlands), and cloned into similarly 
digested pET-21b(+), yielding plasmid pET21B/Axc. The axc expression region was confirmed using Sanger 
sequencing. Expression of Axc-his6 was carried out in E. coli C43(DE3)27 in Luria-Bertani broth (Affymetrix, 
Cleveland, OH, USA) with ampicillin (50 µg/mL) and 1 mM IPTG (GC Biotech, Alphen aan de Rijn, the 
Netherlands) for 3 hrs at 37 °C and verified by immunoblotting using anti-His antibody (Agilent Technologies, 
Santa Clara, CA, USA).
Susceptibility testing of E. coli expressing Axc. Minimal inhibitory concentration (MIC) values for 
the carbapenems imipenem (Etest, BioMérieux) and meropenem (microbroth dilution) were established for E. 
coli C43/pET21B-Axc (strain JC107, Table 1) in the presence and absence of 1 mM IPTG. For imipenem, cells 
were grown overnight in LB broth at 37 °C in the presence of ampicillin (50 µg/mL). The overnight cultures were 
diluted 1:100 in LB broth with ampicillin and grown to mid logarithmic phase (OD600nm ~ 0.5). Two hundred μl of 
bacterial culture was spread on LB-ampicillin (50 µg/mL) plates (with or without 1 mM IPTG) and an Imipenem 
Etest (BioMérieux) was applied. MIC values were determined after 24 h incubation at 37 °C. The meropenem 
MIC values were established by microbroth dilution. Bacterial cultures in logarithmic phase (OD600nm ~ 0.5) were 
diluted into LB-ampicillin medium to an OD600nm of 0.05 in the presence or absence of 1 mM IPTG and subse-
quently seeded in a 96-well plate. A two-fold serial dilution of meropenem (starting at 12.5 µg/mL) was made by 
adding equal amounts of meropenem (25 µg/mL) to the first row, from which a two-fold dilution series was made 
in the rest of the plate. Samples were investigated for growth by measuring the OD600nm after 24 hrs incubation 
at 37 °C, while shaking. The MIC was the lowest concentration of meropenem at which no growth was observed. 
As controls for our assays, a carbapenem resistant Klebsiella pneumoniae clinical isolate (KPC; JC113) and an 
unrelated expression construct (JC108; which expresses PPEP-128 in an IPTG-dependent manner in the same E. 
coli C43 background, Table 2) were included.
Colorimetric imipenem hydrolysis assay. Overnight bacterial cultures were diluted 100 fold in 
LB-ampicillin (50 µg/mL) medium and grown to exponential growth phase at 37 °C while shaking. At the time of 
induction, the OD600nm was determined, the cultures were split in two and 1 mM IPTG was added to one of the 
cultures, followed by a further incubation for 3 hrs at 37 °C while shaking. At T = 3 h, the OD600nm was determined 
Name 5′ > 3′ sequence Description
AxFor 5′-GAATGACATGTTGACCCGAAGAACCTTCATTGCC-3′ axc ORF forward
AxRev 5′-GCCGGATCCCTAGCCCAATGCCGCCACCAGCCTG-3′ axc ORF reverse
Operonfor 5′-CTGAGCATCAGGAAGCGTT-3′ axc-axcR intergenic region forward
Operonrev 5′-TCGAAGGATTCGGACAACAC-3′ axc-axcR intergenic region reverse
AC_RR_fw 5′-AGAAGAATCCCAACGCACCC-3′ Confirmation of SNP in axyZ, forward
AC_RR_rv 5′-TCGAGGCATACAGCGATTCC-3′ Confirmation of SNP in axyZ, reverse
Axfor2 5′-AAACATATGTTGACCCGAAGAACCTTCATTG-3′ Cloning axc ORF into pET21B forward
Axrev3 5′-AAACTCGAGGCCCAATGCCGCCACCAGCC-3′ Cloning axc ORF into pET21B reverse
Table 3. Primers used in this study. Axc: Achromobacter xylosoxidans carbapenemase. axcR: axc-associated 
regulator. axyZ: TetR-type repressor of the axyXY-oprZ operon36.
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and cells were harvested by centrifugation (4000 g, 5 min) and stored at −20 °C overnight. Cells were resuspended 
in water to yield equal densities based on measured OD600nm values. Then, 7.5 µL of bacterial suspension was 
mixed with 25 µL of imipenem/phenol red/ZnSO4 solution (3 mg/mL imipenem, 0.35% (wt/vol) phenol red, pH 
7.8, 70 µM ZnSO4) and incubated at 37 °C for 1 hr. Conversion of imipenem leads to a pH drop that can be vis-
ualized by the color change of the buffer from red to yellow29. To quantify this effect, the UV-Vis spectrum was 
determined with a Nanodrop ND1000 spectrophotometer (Thermo Scientific) and the ratio between the absorp-
tion peaks at 431 and 560 nm was taken as a measure of imipenem hydrolysis.
NMR spectroscopy of imipenem conversion. All proton nuclear magnetic resonance (1H-NMR) exper-
iments were performed on a 600 MHz Bruker Avance II spectrometer (Bruker BioSpin, Karlsruhe, Germany) 
equipped with a 5-mm triple resonance inverse (TCI) cryogenic probe head with a Z-gradient system and auto-
matic tuning and matching. All experiments were recorded at 310 K. Temperature calibration was done before each 
batch of measurements55. The duration of the π/2 pulses was automatically calibrated for each individual sample 
using a homonuclear-gated nutation experiment on the locked and shimmed samples after automatic tuning and 
matching of the probe head. The samples were prepared by adding 70 µL imipenem aqueous solution (5 mg/mL) 
to 280 µL milliQ water. This solution was mixed with 350 µL 75 mM phosphate buffer (pH 7.4) in water/deuterium 
oxide (80/20) containing 4.6 mM sodium 3-[trimethylsilyl] d4-propionate. Twenty µL of bacterial cell suspension 
were added and the sample was mixed. Samples were manually transferred into 5-mm SampleJet NMR tubes. The 
cell suspension samples were kept at 6 °C on a SampleJet sample changer while queued for acquisition. For water 
suppression, presaturation of the water resonance with an effective field of γB1 = 25 Hz was applied during the 
relaxation delay. A 1D-version of the NOESY (Nuclear Overhauser effect spectroscopy) experiment was performed 
with a relaxation delay of 4 seconds. A NOESY mixing time of 10 ms was used during which the water resonance 
was irradiated with the presaturation RF field. After applying 4 dummy scans, a total of 98,304 data points covering 
a spectral width of 18,029 Hz were collected using 16 scans. The Free Induction Decay was zero-filled to 131,072 
complex data points, and an exponential window function was applied with a line broadening factor of 0.3 Hz 
before Fourier transformation. The spectra were automatically phased and baseline corrected.
Bioinformatic analysis. Comparison of Axc with other class A beta lactamases was performed by multi-
ple alignment using the Geneious 9.0 (Biomatters Ltd, Auckland, New Zealand) software algorithm for Global 
alignment with free end gaps, cost Matrix Blosum62. The tree was then built using Jukes-Cantor genetic distance 
model with the Neighbor Joining tree build method.
Data availability. Illumina raw reads were deposited at the European Nucleotide Archive (ENA). Study ID: 
PRJEB19781. Sample IDs: ERS1575148 (AchroR) and ERS1575149 (AchroS).
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